T. Schneider / Shutterstock.com
21 July 2022AmericasStaff writer
Generic maker pays $145m to settle antitrust suit
California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
7 June 2021 Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
Big Pharma
5 July 2022 The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.
Editor's picks
Editor's picks
Big Pharma
7 June 2021 Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
Big Pharma
5 July 2022 The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.
Big Pharma
7 June 2021 Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
Big Pharma
5 July 2022 The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.